Allogene Therapeutics (ALLO) vs Artiva Biotherapeutics (ARTV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Artiva Biotherapeutics (ARTV) has outperformed Allogene Therapeutics (ALLO) over the past year, gaining 20.8% versus a loss of 49.0%. Allogene Therapeutics is the larger company by market cap ($217.5 million vs $186.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | ARTV |
|---|---|---|
| Share price | $0.6277 | $3.78 |
| Market cap | $217.48M | $186.85M |
| 1-day change | -5.88% | -1.31% |
| YTD return | -54.18% | -11.89% |
| 1-year return | -48.97% | +20.77% |
| 5-year return | -96.51% | — |
| EPS (TTM) | $-0.61 | $-2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $0 |
| Revenue growth (YoY) | -100.00% | -100.00% |
| Net income (latest FY) | $-190.89M | $-83.86M |
| 52-week high | $4.46 | $14.53 |
| 52-week low | $0.6192 | $2.96 |
| Distance from 52-week high | -85.93% | -73.98% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +1333.81% | +448.94% |
| Average volume | 7.69M | 792.26K |
| Shares outstanding | 346.47M | 49.43M |
| Employees | 150 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARTV has outperformed ALLO by 69.7 percentage points over the past year.
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
ALLO vs ARTV FAQ
Which is bigger, Allogene Therapeutics or Artiva Biotherapeutics?
Allogene Therapeutics (ALLO) is larger, with a market capitalization of $217.48M compared with $186.85M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ALLO or ARTV?
ARTV returned +20.77% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Artiva Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.